← Telix Pharmaceuticals Ltd (TLPPF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Telix Pharmaceuticals Ltd (TLPPF)
Biotechnology · market cap $4.0B · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-15 (est.)
Phase 3
Pipeline
6
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Telix Pharmaceuticals Ltd (TLPPF) is a biotechnology company with a market cap of approximately $2.63B, focused on radiopharmaceuticals for oncology. Its lead clinical assets include 68Ga-PSMA-11 in Phase 3 for prostate cancer and 177Lu-DOTA-TLX591 in Phase 2 for prostate cancer. The nearest binary event is a PDUFA date of November 15, 2026 for TLX250-CDx, a separate imaging diagnostic asset.
The catalyst path
- 2027-01-15 (est.)Phase 3 · 68Ga-PSMA-11imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| 68Ga-PSMA-11 | Phase 3 | PCA |
| 177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer |
| Fluciclovine F18 | Phase 2 | Prostate Adenocarcinoma |
| PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC | Phase 2 | Prostate Cancer |
| Zirconium Zr 89 Girentuximab | Phase 2 | Clear Cell Renal Cell Carcinoma |
| 177Lu girentuximab | Phase 2 | Advanced Cancer |
Price & technical context
3-month
-5.1%
6-month
+20.5%
12-month
+13.7%
52-wk range
$6.50–$12.55
vs 50-day MA
+0.6%
vs 200-day MA
+18.8%
Realized vol
71.8%
Max drawdown
-68.1%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TLPPF (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.